AstraZeneca: US Court Affirms Seroquel Summary Judgment
September 28 2009 - 2:46AM
Dow Jones News
AstraZeneca PLC (AZN), an International healthcare company, said
Monday the U.S. Court of Appeals for the Federal Circuit has
affirmed the summary judgment decision of no inequitable conduct in
patent litigation involving Seroquel (quetiapine fumarate)
tablets.
MAIN FACTS:
-Most recent decision upholds the District Court's judgment that
Teva Pharmaceutical Industries Ltd.'s (TEVA)and Sandoz's products
will infringe AstraZeneca's Seroquel patent and that the patent is
valid and enforceable.
-AstraZeneca had sued Teva Pharmaceutical and Sandoz, Inc.
alleging infringement of AstraZeneca's patent as a result of Teva's
and Sandoz's filings of abbreviated new drug applications.
-The patent covering Seroquel expires in September 2011, with
paediatric exclusivity through March 2012.
-Since Federal Circuit Court of Appeals' affirmed Summary
Judgment in favor of AstraZeneca, trial remains unnecessary.
-By London Bureau, Dow Jones Newswires; Contact Ian Walker; +44 (0)20 7842 9296; ian.walker@dowjones.com
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024